['\xe2\x86\x91 INDICATES INCREASE.', 'A ONLYIF OTHER DRUGS ARE NOT AVAILABLE AND IF CLEARLY INDICATED. IF TREATMENT WITHLIFE-SUSTAINING DRUGS THAT CAUSE PANCREATIC TOXICITY IS REQUIRED, SUSPENSIONOF VIDEX EC IS RECOMMENDED [ SEE WARNINGS AND PRECAUTIONS (5.1) ].', 'B [ SEEWARNINGS AND PRECAUTIONS (5.6) .]', 'DRUGS THAT MAY CAUSE PANCREATIC TOXICITY', '\xe2\x86\x91 RISK OF PANCREATITIS', 'USE ONLY WITH EXTREME CAUTION. A', 'NEUROTOXIC DRUGS', '\xe2\x86\x91 RISK OF NEUROPATHY', 'USE WITH CAUTION. B'], '\xe2\x86\x93 DIDANOSINE CONCENTRATION', 'IF COADMINISTRATION OF METHADONE AND DIDANOSINE IS NECESSARY, THE RECOMMENDED FORMULATION OF DIDANOSINE IS VIDEX EC. PATIENTS SHOULD BE CLOSELY MONITORED FOR ADEQUATE CLINICAL RESPONSE WHEN VIDEX EC IS COADMINISTERED WITH METHADONE, INCLUDING MONITORING FOR CHANGES IN HIV RNA VIRAL LOAD. DO NOT COADMINISTER METHADONE WITH VIDEX PEDIATRIC POWDER DUE TO SIGNIFICANT DECREASES IN DIDANOSINE CONCENTRATIONS.', 'NELFINAVIR', 'NO INTERACTION 1 HOUR AFTER DIDANOSINE', 'ADMINISTER NELFINAVIR 1 HOUR AFTER VIDEX EC.', 'TENOFOVIR DISOPROXILFUMARATE', '\xe2\x86\x91 DIDANOSINE CONCENTRATION', 'A DOSE REDUCTION OF VIDEX EC TO THEFOLLOWING DOSAGE ONCE DAILY TAKEN TOGETHER WITH TENOFOVIR DISOPROXIL FUMARATEAND A LIGHT MEAL (400 KCALORIES OR LESS AND 20% FAT OR LESS) OR IN THE FASTEDSTATE IS RECOMMENDED. A 250 MG (ADULTS WEIGHING AT LEAST 60 KG WITH CREATININE CLEARANCEOF AT LEAST 60 ML/MIN) 200 MG (ADULTS WEIGHING LESS THAN 60 KG WITH CREATININE CLEARANCEOF AT LEAST 60 ML/MIN) PATIENTS SHOULD BE MONITORED FOR DIDANOSINE-ASSOCIATED TOXICITIES ANDCLINICAL RESPONSE.']